Differential Expression of Axl and Correlation with Invasion and Multidrug Resistance in Cancer Cells

REFERENCES

• Chan HS, Thorner PS, Haddad G, Ling V. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990;8:689–704.
   PubMed Web of Science ®Google Scholar
• Verrelle P, Meissonnier F, Fonck Y, Feillel V, Dionet C, Kwiatkowski F, Plagne R, Chassagne J. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 1991;83: 111–116.
   PubMed Web of Science ®Google Scholar
• Yang JM, Yang GY, Medina DJ, Vassil AD, Liao J, Hait WN. Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the disease. BBRC 1999;266:167–173.
   PubMed Web of Science ®Google Scholar
• Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, Klusens LF, Grogan TM, Saclarides TJ, Roninson IB. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991;51:2720–2726.
   PubMed Web of Science ®Google Scholar
• Hafizi S, Dahlback B. Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev 2006;17:295–304.
   PubMed Web of Science ®Google Scholar
• O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, Espinosa R 3rd, Le Beau MM, Earp HS, Liu ET. Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 1991;11:5016–5031.
   PubMed Web of Science ®Google Scholar
• Rochlitz C, Lohri A, Bacchi M, Schmidt M, Nagel S, Fopp M, Fey MF, Herrmann R, Neubauer A. Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). Leukemia 1999;13:1352–1358.
   PubMed Web of Science ®Google Scholar
• Shieh YS, Lai CY, Kao YR, Shiah SG, Chu YW, Lee HS, Wu CW. Expression of Axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia 2005;7:1058–1064.
   PubMed Web of Science ®Google Scholar
• Chung BI, Malkowicz SB, Nguyen TB, Libertino JA, McGarvey TW. Expression of the proto-oncogene Axl in renal cell carcinoma. DNA Cell Biol 2003;22:533–540.
   PubMed Web of Science ®Google Scholar
• Sainaghi PP, Castello L, Bergamasco L, Galletti M, Bellosta P, Avanzi GC. Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol 2005;204:36–44.
   PubMed Web of Science ®Google Scholar
• Meric F, Lee WP, Sahin A, Zhang H, Kung HJ, Hung MC. Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res 2002;8:361–367.
   PubMed Web of Science ®Google Scholar
• Wu CW, Li AF, Chi CW, Lai CH, Huang CL, Lo SS, Lui WY, Lin WC. Clinical significance of Axl kinase family in gastric cancer. Anticancer Res 2002;22:1071–1078.
   PubMed Web of Science ®Google Scholar
• Holland SJ, Powell MJ, Franci C, Chan EW, Friera AM, Atchison RE, McLaughlin J, Swift SE, Pali ES, Yam G, Wong S, Lasaga J, Shen MR, Yu S, Xu W, Hitoshi Y, Bogenberger J, Nör JE, Payan DG, Lorens JB. Multiple roles for the receptor tyrosine kinase Axl in tumor formation. Cancer Res 2005;65:9294–9303.
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, Wisner L, Iorio M, Shakalya K, Garewal H, Nagle R, Bearss D. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 2007;26:3909–3919.
   PubMed Web of Science ®Google Scholar
• Hong CC, Lay JD, Huang JS, Cheng AL, Tang JL, Lin MT, Lai GM, Chuang SE. Receptor tyrosine kinase Axl is induced by chemotherapy drugs and overexpression of Axl confers drug resistance in acute myeloid leukemia. Cancer Lett 2008;268:314–324.
   PubMed Web of Science ®Google Scholar
• Lay JD, Hong CC, Huang JS, Yang YY, Pao CY, Liu CH, Lai YP, Lai GM, Cheng AL, Su IJ, Chuang SE. Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing Axl. Cancer Res 2007;67:588–599.
   Web of Science ®Google Scholar
• Macleod K, Mullen P, Sewell J, Rabiasz G, Lawrie S, Miller E, Smyth JF, Langdon SP. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res 2005;65:6789–6800.
   PubMed Web of Science ®Google Scholar
• Challier C, Uphoff CC, Janssen JW, Drexler HG. Differential expression of the Ufo/Axl oncogene in human leukemia-lymphoma cell lines. Leukemia 1996;10:781–787.
   PubMed Web of Science ®Google Scholar
• Krishna R, Mayer LD. Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators. Curr Med Chem Anti-Cancer Agents 2001;1:163–174.
   PubMedGoogle Scholar
• Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol 1999;128:403–411.
   PubMed Web of Science ®Google Scholar
• Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R. Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 2000;58:624–632.
   PubMed Web of Science ®Google Scholar
• Kerbel R, Korczak S, Lagarde BA. Growth dominance of the metastatic cancer cell: cellular and molecular aspects. Adv Cancer Res 1990;5:87–132.
   Google Scholar
• Su ZZ, Austin VN, Zimmer SG, Fisher PB. Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells. Oncogene 1993;8:1211–1219.
   PubMed Web of Science ®Google Scholar
• Keating AK, Kim GK, Jones AE, Donson AM, Ware K, Mulcahy JM, Salzberg DB, Foreman NK, Liang X, Thorburn A, Graham DK. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther 2010;9:1298–1307.
   PubMed Web of Science ®Google Scholar
• Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004;4:361–370.
   PubMed Web of Science ®Google Scholar
• Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin AM, Gilmer TM. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of Axl. Cancer Res 2009;69:6871–6878.
   PubMed Web of Science ®Google Scholar
• Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, Szabadkai I, Daub H, Kéri G, Ullrich A. Axl is a potential target for therapeutic intervention in breast cancer progression. Cancer Res 2008;68:1905–1915.
   PubMed Web of Science ®Google Scholar